---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-261658"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2026-06-08T20:01:05+00:00"
generated_at: "2026-06-08T20:02:56.299205+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma stockholders elect three Class II directors and ratify auditor at 2026 annual meeting

## Summary
- Directors Jane Chung (11.4M for), Connie Matsui (9.7M for), James Panek (9.7M for) elected to three-year terms.
- Ratification of Ernst & Young as auditor for 2026 passed with 13.9M for, 501 against.
- Non-binding advisory vote on named executive officer compensation approved with 11.3M for.
- Broker non-votes totaled 2,540,863 on director election and say-on-pay items.

## SEC filing metadata
- accession: 0001193125-26-261658
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2026-06-08T20:01:05+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000119312526261658/0001193125-26-261658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000119312526261658/d116098d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-261658
- JSON: https://secwatch.observer/filing/0001193125-26-261658.json
- Plain text: https://secwatch.observer/filing/0001193125-26-261658.txt

## Key facts
- Shareholder Votes
  SUTRO BIOPHARMA, INC. shareholders approved Election of three Class II directors at the 2026-06-05 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: On June 5, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”), and the following proposals were adopted: 1. Election of three Class II directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000119312526261658/0001193125-26-261658-index.htm
- Shareholder Votes
  SUTRO BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-05 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: 2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Shares For Shares Against Shares Abstaining 13,893,289 501 5,883
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000119312526261658/0001193125-26-261658-index.htm
- Shareholder Votes
  SUTRO BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting at the 2026-06-05 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: 3. Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting: Shares For Shares Against Shares Abstaining Broker Non-Votes 11,329,946 22,412 6,452 2,540,863
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000119312526261658/0001193125-26-261658-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.